Skip to main content
SpringerLink
Log in

Prostate Cancer

  • Reference work entry
  • First Online:
Geriatric Medicine

  • 371 Accesses

Abstract

Prostate cancer is the most common malignancy in men after skin cancer. The incidence of prostate cancer increases with age, and it is one of the leading causes of death attributable to cancer in men above 60 years of age. Nonetheless, many prostate cancers have a relatively mild severity with limited impact on life expectancy. For this reason, prostate cancer treatment has to be individualized, taking into consideration pre-existing comorbidities and life expectancy of the affected men, offering treatments that range from surveillance up to multimodal treatments including surgery, radiation, and/or androgen deprivation therapy for localized disease, as well as a variety of treatments for more advanced stages.

In the following chapter, we will discuss the particularities of prostate cancer in the older population, and we will describe the available treatments for each stage of disease. Furthermore, we will focus on the implications of frailty on treatment decision-making and on how to focus not only on longevity but also incorporating quality of life into decision-making.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics. CA Cancer J Clin. 2023;73:17–48.

    Google Scholar 

  2. Droz JP, Albrand G, Gillessen S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the international society of geriatric oncology. Eur Urol. 2017;72:521.

    Article  PubMed  Google Scholar 

  3. Briganti A, Karnes RJ, Gandaglia G, et al. Natural history of surgically treated high-risk prostate cancer. Urol Oncol. 2015;33:163 e7.

    Article  PubMed  Google Scholar 

  4. Lee DJ, Mallin K, Graves AJ, et al. Recent changes in prostate cancer screening practices and epidemiology. J Urol. 2017;198:1230.

    Article  PubMed  Google Scholar 

  5. Holm M, Doveson S, Lindqvist O, et al. Quality of life in men with metastatic prostate cancer in their final years before death – a retrospective analysis of prospective data. BMC Palliat Care. 2018;17:126.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Scher HI, Solo K, Valant J, et al. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One. 2015;10:e0139440.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Moreira DM, Howard LE, Sourbeer KN, et al. Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH. Clin Genitourin Cancer. 2017;15:60.

    Article  PubMed  Google Scholar 

  8. Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15:e484.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Bhindi B, Locke J, Alibhai SMH, et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2015;67:64.

    Article  CAS  PubMed  Google Scholar 

  10. Cheng HH, Sokolova AO, Schaeffer EM, et al. Germline and somatic mutations in prostate cancer for the clinician. J Natl Compr Cancer Netw. 2019;17:515.

    Article  CAS  Google Scholar 

  11. Giri VN, Knudsen KE, Kelly WK, et al. Role of genetic testing for inherited prostate cancer risk: philadelphia prostate cancer consensus conference 2017. J Clin Oncol. 2018;36:414.

    Article  CAS  PubMed  Google Scholar 

  12. Butler EN, Kelly SP, Coupland VH, et al. Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment. Br J Cancer. 2020;123:487.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Powell IJ, Bock CH, Ruterbusch JJ, et al. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010;183:1792.

    Article  PubMed  Google Scholar 

  14. Fletcher SA, Marchese M, Cole AP, et al. Geographic distribution of racial differences in prostate cancer mortality. JAMA Netw Open. 2020;3:e201839.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Halabi S, Dutta S, Tangen CM, et al. Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration resistant prostate cancer. Ann Oncol. 2020;31:930.

    Article  CAS  PubMed  Google Scholar 

  16. Thorpe RJ Jr, Bruce MA, Howard DL, et al. Race differences in mobility status among prostate cancer survivors: the role of socioeconomic status. Adv Cancer Res. 2020;146:103.

    Article  PubMed  Google Scholar 

  17. Vidal AC, Oyekunle T, Howard LE, et al. Obesity, race, and long-term prostate cancer outcomes. Cancer. 2020;126:3733.

    Article  CAS  PubMed  Google Scholar 

  18. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320.

    Article  PubMed  Google Scholar 

  20. Heijnsdijk EAM, Adolfsson J, Auvinen A, et al. The impact of design and performance in prostate-specific antigen screening: differences between ERSPC centers. Eur Urol. 2019;76:276.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hugosson J, Godtman RA, Carlsson SV, et al. Eighteen-year follow-up of the goteborg randomized population-based prostate cancer screening trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol. 2018;52:27.

    Article  PubMed  Google Scholar 

  22. Hugosson J, Roobol MJ, Mansson M, et al. A 16-yr follow-up of the european randomized study of screening for prostate cancer. Eur Urol. 2019;76:43.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Villers A, Bessaoud F, Tretarre B, et al. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC). Prog Urol. 2020;30:252.

    Article  CAS  PubMed  Google Scholar 

  24. Drazer MW, Prasad SM, Huo D, et al. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014;120:1491.

    Article  PubMed  Google Scholar 

  25. Goodwin JS, Jaramillo E, Yang L, et al. Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States preventive services task force recommendations against it: a retrospective cohort study. PLoS One. 2014;9:e107352.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314:2054.

    Article  CAS  PubMed  Google Scholar 

  27. Lee SY, Friderici J, Stefan MS, et al. Impact of the 2008 U.S. Preventative Services Task Force recommendation on frequency of prostate-specific antigen screening in older men. J Am Geriatr Soc. 2014;62:1912.

    Article  PubMed  Google Scholar 

  28. Scosyrev E, Wu G, Golijanin D, et al. Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system. BJU Int. 2012;110:1485.

    Article  PubMed  Google Scholar 

  29. Herget KA, Patel DP, Hanson HA, et al. Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score. Cancer Med. 2016;5:136.

    Article  PubMed  Google Scholar 

  30. Hu JC, Nguyen P, Mao J, et al. Increase in prostate cancer distant metastases at diagnosis in the United States. JAMA Oncol. 2017;3:705.

    Article  PubMed  Google Scholar 

  31. Tan GH, Nason G, Ajib K, et al. Smarter screening for prostate cancer. World J Urol. 2019;37:991.

    Article  CAS  PubMed  Google Scholar 

  32. Schoots IG, Roobol MJ, Nieboer D, et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol. 2015;68:438.

    Article  PubMed  Google Scholar 

  33. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Williamson DA, Barrett LK, Rogers BA, et al. Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. Clin Infect Dis. 2013;57:267.

    Article  PubMed  Google Scholar 

  35. Omer A, Lamb AD. Optimizing prostate biopsy techniques. Curr Opin Urol. 2019;29:578.

    Article  PubMed  Google Scholar 

  36. Epstein JI, Egevad L, Amin MB, et al. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244.

    Article  PubMed  Google Scholar 

  37. Kulac I, Haffner MC, Yegnasubramanian S, et al. Should gleason 6 be labeled as cancer? Curr Opin Urol. 2015;25:238.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Epstein JI, Amin MB, Reuter VE, et al. Contemporary gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2017;41:e1.

    Article  PubMed  Google Scholar 

  39. Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17:479.

    Article  CAS  Google Scholar 

  40. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103.

    Article  CAS  PubMed  Google Scholar 

  41. Napodano G, Ferro M, Sanseverino R. High-risk prostate cancer: a very challenging disease in the field of uro-oncology. Diagnostics (Basel). 2021;11.

    Google Scholar 

  42. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009;101:878.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Pettersson A, Robinson D, Garmo H, et al. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol. 2018;29:377.

    Article  CAS  PubMed  Google Scholar 

  44. Bratt O, Folkvaljon Y, Hjalm Eriksson M, et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol. 2015;68:53.

    Article  PubMed  Google Scholar 

  45. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618.

    Article  PubMed  Google Scholar 

  46. Martinez-Tapia C, Paillaud E, Liuu E, et al. Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer. Eur J Cancer. 2017;83:211.

    Article  PubMed  Google Scholar 

  47. Bellera CA, Artaud F, Rainfray M, et al. Modeling individual and relative accuracy of screening tools in geriatric oncology. Ann Oncol. 2017;28:1152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Lowenstein LM, Mohile SG, Gil HH, et al. Which better predicts mortality among older men, a prostate cancer (PCa) diagnosis or vulnerability on the Vulnerable Elders Survey (VES-13)? A retrospective cohort study. J Geriatr Oncol. 2016;7:437.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011;29:235.

    Article  PubMed  Google Scholar 

  50. Yang DD, Mahal BA, Muralidhar V, et al. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer. 2017;123:4832.

    Article  CAS  PubMed  Google Scholar 

  51. Hurwitz MD, Harris J, Sartor O, et al. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017;123:2489.

    Article  CAS  PubMed  Google Scholar 

  52. Johansson E, Steineck G, Holmberg L, et al. Quality of life after radical prostatectomy or watchful waiting with or without androgen deprivation therapy: The SPCG-4 randomized trial. Eur Urol Oncol. 2018;1:134.

    Article  PubMed  Google Scholar 

  53. Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017;377:132.

    Article  PubMed  Google Scholar 

  54. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977.

    Article  CAS  PubMed  Google Scholar 

  55. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Barbosa PV, Thomas IC, Srinivas S, et al. Overall survival in patients with localized prostate cancer in the US veterans health administration: Is PIVOT generalizable? Eur Urol. 2016;70:227.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Dalela D, Karabon P, Sammon J, et al. Generalizability of the prostate cancer intervention versus observation trial (PIVOT) results to contemporary North American men with prostate cancer. Eur Urol. 2017;71:511.

    Article  PubMed  Google Scholar 

  58. Neal DE, Metcalfe C, Donovan JL, et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. Eur Urol. 2020;77:320.

    Article  PubMed  Google Scholar 

  59. Cooperberg MR, Vickers AJ, Broering JM, et al. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116:5226.

    Article  PubMed  Google Scholar 

  60. Wallis CJD, Glaser A, Hu JC, et al. Survival and complications following surgery and radiation for localized prostate cancer: an international collaborative review. Eur Urol. 2018;73:11.

    Article  PubMed  Google Scholar 

  61. Abdollah F, Sun M, Thuret R, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol. 2011;59:88.

    Article  PubMed  Google Scholar 

  62. Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007;25:3576.

    Article  PubMed  Google Scholar 

  63. Tsao CK, Gray KP, Nakabayashi M, et al. Patients with biopsy gleason 9 and 10 prostate cancer have significantly worse outcomes compared to patients with gleason 8 disease. J Urol. 2015;194:91.

    Article  PubMed  Google Scholar 

  64. Klotz L. Active surveillance for low-risk prostate cancer. Curr Opin Urol. 2017;27:225.

    Article  PubMed  Google Scholar 

  65. Dall’Era MA, Klotz L. Active surveillance for intermediate-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017;20:1.

    Article  PubMed  Google Scholar 

  66. Chandrasekar T, Herrera-Caceres JO, Klotz L. Active surveillance in intermediate risk prostate cancer. Arch Esp Urol. 2019;72:157.

    PubMed  Google Scholar 

  67. Klotz L, Loblaw A, Sugar L, et al. Active surveillance magnetic resonance imaging study (ASIST): results of a randomized multicenter prospective trial. Eur Urol. 2019;75:300.

    Article  PubMed  Google Scholar 

  68. Herrera-Caceres JO, Wettstein MS, Goldberg H, et al. Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. Can Urol Assoc J. 2020;14:E453.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Gandaglia G, Martini A, Ploussard G, et al. External validation of the 2019 briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection. Eur Urol. 2020;78:138.

    Article  PubMed  Google Scholar 

  70. Dell’Oglio P, Mottrie A, Mazzone E. Robot-assisted radical prostatectomy vs. open radical prostatectomy: latest evidences on perioperative, functional and oncological outcomes. Curr Opin Urol. 2020;30:73.

    Article  PubMed  Google Scholar 

  71. Yaxley JW, Coughlin GD, Chambers SK, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet. 2016;388:1057.

    Article  PubMed  Google Scholar 

  72. Shoag JE, Cai PY, Gross MD, et al. Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance. Cancer. 2020;126:2986.

    Article  PubMed  Google Scholar 

  73. Wallis CJD, Saskin R, Choo R, et al. Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:21.

    Article  PubMed  Google Scholar 

  74. Alibhai SM, Leach M, Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst. 2005;97:1525.

    Article  PubMed  Google Scholar 

  75. Briganti A, Spahn M, Joniau S, et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol. 2013;63:693.

    Article  PubMed  Google Scholar 

  76. Dell’Oglio P, Zaffuto E, Boehm K, Trudeau V, Larcher A, Tian Z, Moschini M, Shariat SF, Graefen M, Saad F, Capitanio U, Briganti A, Montorsi F, Karakiewicz PI. Long-term survival of patients aged 80 years or older treated with radical prostatectomy for prostate cancer. Eur J Surg Oncol. 2017;43:8.

    Google Scholar 

  77. Dasgupta M, Rolfson DB, Stolee P, et al. Frailty is associated with postoperative complications in older adults with medical problems. Arch Gerontol Geriatr. 2009;48:78.

    Article  PubMed  Google Scholar 

  78. Robinson TN, Eiseman B, Wallace JI, et al. Redefining geriatric preoperative assessment using frailty, disability and co-morbidity. Ann Surg. 2009;250:449.

    Article  PubMed  Google Scholar 

  79. Vernooij RWM, Cremers R, Jansen H, et al. Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study. Urol Oncol. 2020;38:735.e17.

    Article  CAS  PubMed  Google Scholar 

  80. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250.

    Article  CAS  PubMed  Google Scholar 

  81. Basto MY, Vidyasagar C, te Marvelde L, et al. Early urinary continence recovery after robot-assisted radical prostatectomy in older Australian men. BJU Int. 2014;114(Suppl 1):29.

    Article  PubMed  Google Scholar 

  82. Barocas DA, Alvarez J, Resnick MJ, et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA. 2017;317:1126.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Chen RC, Basak R, Meyer AM, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA. 2017;317:1141.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Matta R, Hird AE, Saskin R, et al. Is there an association between urinary incontinence and mortality? A retrospective cohort study. J Urol. 2020;203:591.

    Article  PubMed  Google Scholar 

  85. Bekelman JE, Mitra N, Handorf EA, et al. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. J Clin Oncol. 2015;33:716.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Nabid A, Carrier N, Martin AG, et al. Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol. 2018;74:432.

    Article  CAS  PubMed  Google Scholar 

  87. Palma D, Vollans E, James K, et al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:996.

    Article  PubMed  Google Scholar 

  88. Kollmeier MA, McBride S, Varghese M, et al. Low dose rate brachytherapy combined with ultra-hypofractionated radiation therapy for clinically localized, intermediate-risk prostate cancer: results from a prospective trial. Int J Radiat Oncol Biol Phys. 2020;108:905.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Ekanger C, Helle SI, Heinrich D, et al. Ten-year results from a phase II study on image guided, intensity modulated radiation therapy with simultaneous integrated boost in high-risk prostate cancer. Adv Radiat Oncol. 2020;5:396.

    Article  PubMed  Google Scholar 

  90. Crook JM, Tang C, Thames H, et al. A biochemical definition of cure after brachytherapy for prostate cancer. Radiother Oncol. 2020;149:64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Liberman D, Mehus B, Elliott SP. Urinary adverse effects of pelvic radiotherapy. Transl Androl Urol. 2014;3:186.

    PubMed  PubMed Central  Google Scholar 

  92. Lee HJ Jr, Macomber MW, Spraker MB, et al. Analysis of gastrointestinal toxicity in patients receiving proton beam therapy for prostate cancer: a single-institution experience. Adv Radiat Oncol. 2019;4:70.

    Article  PubMed  Google Scholar 

  93. Studer UE, Collette L, Whelan P, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol. 2008;53:941.

    Article  PubMed  Google Scholar 

  94. Kawakami J, Cowan JE, Elkin EP, et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006;106:1708.

    Article  PubMed  Google Scholar 

  95. Sammon JD, Abdollah F, Reznor G, et al. Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer. Eur Urol. 2015;68:32.

    Article  PubMed  Google Scholar 

  96. Keating NL, O’Malley AJ, McNaughton-Collins M, et al. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int. 2008;101:1077.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Bylow K, Mohile SG, Stadler WM, et al. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer. 2007;110:2604.

    Article  CAS  PubMed  Google Scholar 

  98. Galvao DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102:44.

    Article  PubMed  Google Scholar 

  99. Albertsen PC, Moore DF, Shih W, et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29:1335.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Bylow K, Dale W, Mustian K, Stadler WM, Rodin M, Hall W, Lachs M, Mohile SG. Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology. 2008;72:6.

    Article  Google Scholar 

  101. Kulseth MA, Fagerlund A, Myrset AH. Affinity selection using filamentous phage display. Methods Mol Biol. 2014;1088:67.

    Article  CAS  PubMed  Google Scholar 

  102. Nead KT, Gaskin G, Chester C, et al. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2017;3:49.

    Article  PubMed  Google Scholar 

  103. Zhang Z, Yang L, Xie D, et al. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: a 15-month prospective, observational study. Psychooncology. 2017;26:2238.

    Article  PubMed  Google Scholar 

  104. Alibhai SM, Breunis H, Timilshina N, et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol. 2010;28:5038.

    Article  CAS  PubMed  Google Scholar 

  105. Mohile SG, Lacy M, Rodin M, et al. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit Rev Oncol Hematol. 2010;75:152.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Krahn MD, Bremner KE, Luo J, et al. Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events. Curr Oncol. 2014;21:e457.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Hershman DL, Unger JM, Wright JD, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016;2:453.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238.

    Article  CAS  PubMed  Google Scholar 

  110. Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825.

    Article  CAS  PubMed  Google Scholar 

  111. Barry MJ, Delorenzo MA, Walker-Corkery ES, et al. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int. 2006;98:973.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Keating NL. Type of androgen deprivation therapy and risk of cardiovascular disease. Eur Urol. 2017;72:929.

    Article  PubMed  Google Scholar 

  113. Krahn MD, Bremner KE, Luo J, et al. Long-term health care costs for prostate cancer patients on androgen deprivation therapy. Curr Oncol. 2016;23:e443.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Sun M, Choueiri TK, Hamnvik OP, et al. Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy. JAMA Oncol. 2016;2:500.

    Article  PubMed  Google Scholar 

  115. Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382:2187.

    Article  CAS  PubMed  Google Scholar 

  116. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781.

    Article  CAS  PubMed  Google Scholar 

  117. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472.

    Article  CAS  PubMed  Google Scholar 

  118. Wong YN, Freedland S, Egleston B, et al. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol. 2009;27:100.

    Article  PubMed  Google Scholar 

  119. Crook JM, O’Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367:895.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Casas F, Henriquez I, Bejar A, et al. Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study. Clin Transl Oncol. 2017;19:373.

    Article  CAS  PubMed  Google Scholar 

  122. Postema AW, De Reijke TM, Ukimura O, et al. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J Urol. 2016;34:1373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Monfardini S, Morlino S, Valdagni R, et al. Follow-up of elderly patients with urogenital cancers: evaluation of geriatric care needs and related actions. J Geriatr Oncol. 2017;8:289.

    Article  PubMed  Google Scholar 

  124. Saad F, Chi KN, Finelli A, et al. The 2015 CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2015;9:90.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502.

    Article  CAS  PubMed  Google Scholar 

  127. Droz JP, Efstathiou E, Yildirim A, et al. First-line treatment in senior adults with metastatic castration-resistant prostate cancer: a prospective international registry. Urol Oncol. 2016;34:234 e21.

    Article  PubMed  Google Scholar 

  128. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Horgan AM, Seruga B, Pond GR, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol. 2014;5:119.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Hervonen P, Joensuu H, Joensuu T, et al. Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer. Anticancer Res. 2012;32:953.

    CAS  PubMed  Google Scholar 

  131. Alibhai SM, Aziz S, Manokumar T, et al. A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer. J Geriatr Oncol. 2017;8:31.

    Article  PubMed  Google Scholar 

  132. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995.

    Article  PubMed  PubMed Central  Google Scholar 

  133. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138.

    Article  CAS  PubMed  Google Scholar 

  135. Beardo P, Osman I, San Jose B, et al. Safety and outcomes of new generation hormone-therapy in elderly chemotherapy-naive metastatic castration-resistant prostate cancer patients in the real world. Arch Gerontol Geriatr. 2019;82:179.

    Article  CAS  PubMed  Google Scholar 

  136. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121.

    Article  CAS  PubMed  Google Scholar 

  137. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424.

    Article  PubMed  PubMed Central  Google Scholar 

  139. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187.

    Article  CAS  PubMed  Google Scholar 

  140. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13.

    Article  CAS  PubMed  Google Scholar 

  142. Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408.

    Article  CAS  PubMed  Google Scholar 

  143. Agarwal N, McQuarrie K, Bjartell A, et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2019;20:1518.

    Article  CAS  PubMed  Google Scholar 

  144. Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235.

    Article  CAS  PubMed  Google Scholar 

  145. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411.

    Article  CAS  PubMed  Google Scholar 

  146. Patel A, Fong L. Immunotherapy for prostate cancer: where do we go from here?-PART 1: prostate cancer vaccines. Oncology (Williston Park). 2018;32:112.

    PubMed  Google Scholar 

  147. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213.

    Article  CAS  PubMed  Google Scholar 

  148. Song YP, Ellis T, Walshaw R, et al. Comparing clinical outcomes for radium-223: do older patients do worse? Int J Radiat Oncol Biol Phys. 2017;98:955.

    Article  CAS  PubMed  Google Scholar 

  149. Hoskin P, Sartor O, O’Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397.

    Article  CAS  PubMed  Google Scholar 

  150. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147.

    Article  PubMed  Google Scholar 

  151. Meisel A, von Felten S, Vogt DR, et al. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trial. Eur J Cancer. 2016;56:93.

    Article  CAS  PubMed  Google Scholar 

  152. Bilen MA, Cauley DH, Atkinson BJ, et al. Safety of same-day pegfilgrastim administration in metastatic castration-resistant prostate cancer treated with cabazitaxel with or without carboplatin. Clin Genitourin Cancer. 2017;15:e429.

    Article  PubMed  Google Scholar 

  153. Oudard S, Fizazi K, Sengelov L, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol. 2017;35:3189.

    Article  CAS  PubMed  Google Scholar 

  154. Bahl A, Masson S, Malik Z, et al. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU Int. 2015;116:880.

    Article  CAS  PubMed  Google Scholar 

  155. de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506.

    Article  PubMed  Google Scholar 

  156. Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091.

    Article  PubMed  Google Scholar 

  158. Abida W, Campbell D, Patnaik A, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res. 2020;26:2487.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. Antonarakis ES. Olaparib for DNA repair-deficient prostate cancer – one for all, or all for one? Nat Rev Clin Oncol. 2020;17:455.

    Article  CAS  PubMed  Google Scholar 

  160. Al-Shafa F, Arifin AJ, Rodrigues GB, et al. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: where will the evidence lead? Front Oncol. 2019;9:543.

    Article  PubMed  PubMed Central  Google Scholar 

  161. Saluja R, Cheung P, Zukotynski K, et al. Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: from chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases. Urol Oncol. 2016;34:225.

    Article  CAS  PubMed  Google Scholar 

  162. Triggiani L, Alongi F, Buglione M, et al. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer. 2017;116:1520.

    Article  PubMed  PubMed Central  Google Scholar 

  163. D'Angelillo RM, Francolini G, Ingrosso G, et al. Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: a position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). Crit Rev Oncol Hematol. 2019;138:24.

    Article  PubMed  Google Scholar 

  164. Siva S, Bressel M, Murphy DG, et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74:455.

    Article  PubMed  Google Scholar 

  165. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446.

    Article  CAS  PubMed  Google Scholar 

  166. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051.

    Article  PubMed  Google Scholar 

  167. Browne BM, Vanni AJ. Management of urethral stricture and bladder neck contracture following primary and salvage treatment of prostate cancer. Curr Urol Rep. 2017;18:76.

    Article  PubMed  Google Scholar 

  168. Parry MG, Cowling TE, Sujenthiran A, et al. Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data. Cancer Epidemiol. 2019;63:101628.

    Article  PubMed  Google Scholar 

  169. Tablazon IL, Howard LE, De Hoedt AM, et al. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2019;125:4003.

    Article  PubMed  Google Scholar 

  170. Saylor PJ, Rumble RB, Tagawa S, et al. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care ontario guideline. J Clin Oncol. 2020;38:1736.

    Article  PubMed  Google Scholar 

  171. Guo Y, Ngo-Huang AT, Fu JB. Perspectives on spinal precautions in patients who have cancer and spinal metastasis. Phys Ther. 2020;100:554.

    Article  PubMed  Google Scholar 

  172. Pascoe C, Duncan C, Lamb BW, et al. Current management of radiation cystitis: a review and practical guide to clinical management. BJU Int. 2019;123:585.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Oncology, University of Toronto, University Health Network, Toronto, Canada

    Neil Fleshner

  2. University Health Network, Toronto, Canada

    Shabbir M. H. Alibhai

  3. Department of Urology, Penn State Health, PA, USA

    Jaime O. Herrera-Caceres

Authors
  1. Jaime O. Herrera-Caceres
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil Fleshner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shabbir M. H. Alibhai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaime O. Herrera-Caceres .

Editor information

Editors and Affiliations

  1. California Association of Long Term Care Medicine, Newbury Park, CA, USA

    Michael R. Wasserman

  2. Betty Irene Moore School of Nursing, University of California, Davis, Sacramento, CA, USA

    Debra Bakerjian

  3. Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA

    Sunny Linnebur

  4. Division of Geriatrics, SUNY Upstate Medical University, Syracuse, NY, USA

    Sharon Brangman

  5. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    Matteo Cesari

  6. Section of Geriatric Medicine, Division of Internal Medicine, Department of Medicine, Cedars-Sinai, Beverly Hills, CA, USA

    Sonja Rosen

Section Editor information

  1. Department of Medicine, Geriatrics Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Armin Shahrokni MD

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Herrera-Caceres, J.O., Fleshner, N., Alibhai, S.M.H. (2024). Prostate Cancer. In: Wasserman, M.R., Bakerjian, D., Linnebur, S., Brangman, S., Cesari, M., Rosen, S. (eds) Geriatric Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-74720-6_80

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-74720-6_80

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-74719-0

  • Online ISBN: 978-3-030-74720-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation